Search for other papers by Milou Cecilia Madsen in
Google Scholar
PubMed
Search for other papers by Martin den Heijer in
Google Scholar
PubMed
Search for other papers by Claudia Pees in
Google Scholar
PubMed
Search for other papers by Nienke R Biermasz in
Google Scholar
PubMed
Search for other papers by Leontine E H Bakker in
Google Scholar
PubMed
testosterone-dependent group are transgender people looking for masculinization. These people are birth-assigned female but identify as male or non-binary. To induce virilization, testosterone therapy is prescribed. This includes deepening of the voice
Search for other papers by Peter Bond in
Google Scholar
PubMed
Search for other papers by Tijs Verdegaal in
Google Scholar
PubMed
Search for other papers by Diederik L Smit in
Google Scholar
PubMed
Erythrocytosis, or elevated hematocrit, is a common side effect of testosterone therapy (TTh) in male hypogonadism. Testosterone stimulates erythropoiesis through an initial rise in erythropoietin (EPO), establishment of a new EPO/hemoglobin ‘set point’, and a parallel decrease in the master iron regulator protein hepcidin, as well as several other potential mechanisms. Evidence shows an increased thrombotic risk associated with TTh–induced erythrocytosis. Several guidelines for the treatment of male hypogonadism by endocrine organizations recommend against starting TTh in patients presenting with elevated hematocrit at baseline or to stop TTh when its levels cannot be controlled by dose-adjustments. Importantly, therapeutic phlebotomy or venesection is mentioned as a means of reducing hematocrit in these patients. However, evidence supporting the efficacy or safety of therapeutic phlebotomy in lowering hematocrit in TTh–induced erythrocytosis is lacking. In light of this dearth of evidence, the recommendation to lower hematocrit using therapeutic phlebotomy is notable, as phlebotomy lowers tissue oxygen partial pressure (pO2) and, eventually, depletes iron stores, thereby triggering various biological pathways which might also increase thrombotic risk. The potential pros and cons should therefore be carefully weighed against each other and shared decision making is recommended for initiating therapeutic phlebotomy as a treatment in patients on TTh who present with increased hematocrit.
Unit for Thrombosis Research, Department of Regional Health Research, University of Southern Denmark, Denmark
Search for other papers by Mette Bøgehave in
Google Scholar
PubMed
Department of Clinical Research, University of Southern Denmark, Odense, Denmark
OPEN, Open Patient data Explorative Network, Odense University Hospital, Region of Southern Denmark, Odense, Denmark
Search for other papers by Dorte Glintborg in
Google Scholar
PubMed
Unit for Thrombosis Research, Department of Regional Health Research, University of Southern Denmark, Denmark
Search for other papers by Jørgen Brodersen Gram in
Google Scholar
PubMed
Unit for Thrombosis Research, Department of Regional Health Research, University of Southern Denmark, Denmark
Search for other papers by Else-Marie Bladbjerg in
Google Scholar
PubMed
Department of Clinical Research, University of Southern Denmark, Odense, Denmark
Search for other papers by Marianne Skovsager Andersen in
Google Scholar
PubMed
Unit for Thrombosis Research, Department of Regional Health Research, University of Southern Denmark, Denmark
Search for other papers by Johannes Jakobsen Sidelmann in
Google Scholar
PubMed
significantly different from the placebo group. Corresponding to our findings, previous studies report a reduction in protein C ( 23 ), an increase in free protein S ( 26 ), and no effect on TFPI and antithrombin ( 20 , 22 ) after testosterone therapy. The
International Centre for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health (EDMaRC), Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark
Search for other papers by Hans Valdemar López Krabbe in
Google Scholar
PubMed
International Centre for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health (EDMaRC), Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark
Section of Biostatistics, University of Copenhagen, Copenhagen, Denmark
Search for other papers by Jørgen Holm Petersen in
Google Scholar
PubMed
International Centre for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health (EDMaRC), Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark
Department of Fertility, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
Search for other papers by Louise Laub Asserhøj in
Google Scholar
PubMed
International Centre for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health (EDMaRC), Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark
Search for other papers by Trine Holm Johannsen in
Google Scholar
PubMed
International Centre for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health (EDMaRC), Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark
Search for other papers by Peter Christiansen in
Google Scholar
PubMed
International Centre for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health (EDMaRC), Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark
Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
Search for other papers by Rikke Beck Jensen in
Google Scholar
PubMed
International Centre for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health (EDMaRC), Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark
Search for other papers by Line Hartvig Cleemann in
Google Scholar
PubMed
International Centre for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health (EDMaRC), Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark
Search for other papers by Casper P Hagen in
Google Scholar
PubMed
International Centre for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health (EDMaRC), Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark
Search for other papers by Lærke Priskorn in
Google Scholar
PubMed
International Centre for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health (EDMaRC), Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark
Search for other papers by Niels Jørgensen in
Google Scholar
PubMed
International Centre for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health (EDMaRC), Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark
Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
Search for other papers by Katharina M Main in
Google Scholar
PubMed
International Centre for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health (EDMaRC), Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark
Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
Search for other papers by Anders Juul in
Google Scholar
PubMed
International Centre for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health (EDMaRC), Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark
Search for other papers by Lise Aksglaede in
Google Scholar
PubMed
A . Evaluation of 451 Danish boys with delayed puberty: diagnostic use of a new puberty nomogram and effects of oral testosterone therapy . Journal of Clinical Endocrinology and Metabolism 2015 100 1376 – 1385 . ( https://doi.org/10.1210/jc.2014
Search for other papers by Sakina Kherra in
Google Scholar
PubMed
Search for other papers by Wendy Forsyth Paterson in
Google Scholar
PubMed
Search for other papers by Filiz Mine Cizmecioglu in
Google Scholar
PubMed
Search for other papers by Jeremy Huw Jones in
Google Scholar
PubMed
Search for other papers by Mariam Kourime in
Google Scholar
PubMed
Search for other papers by Heba Hassan Elsedfy in
Google Scholar
PubMed
Search for other papers by Sameh Tawfik in
Google Scholar
PubMed
Search for other papers by Andreas Kyriakou in
Google Scholar
PubMed
Search for other papers by Mohamad Guftar Shaikh in
Google Scholar
PubMed
Search for other papers by Malcolm David Cairns Donaldson in
Google Scholar
PubMed
point per patient per age band. Median (range) values are shown. Testosterone values post hCG given to 16/19 patients prior to surgery and to 9 patients to test Leydig cell reserve are shown. Data does not include patients on testosterone therapy
Search for other papers by Sebastian Franik in
Google Scholar
PubMed
Search for other papers by Kathrin Fleischer in
Google Scholar
PubMed
Search for other papers by Barbara Kortmann in
Google Scholar
PubMed
Search for other papers by Nike M Stikkelbroeck in
Google Scholar
PubMed
Search for other papers by Kathleen D’Hauwers in
Google Scholar
PubMed
Search for other papers by Claire Bouvattier in
Google Scholar
PubMed
Search for other papers by Jolanta Slowikowska-Hilczer in
Google Scholar
PubMed
Search for other papers by Solange Grunenwald in
Google Scholar
PubMed
Search for other papers by Tim van de Grift in
Google Scholar
PubMed
Search for other papers by Audrey Cartault in
Google Scholar
PubMed
Search for other papers by Annette Richter-Unruh in
Google Scholar
PubMed
Search for other papers by Nicole Reisch in
Google Scholar
PubMed
Search for other papers by Ute Thyen in
Google Scholar
PubMed
Search for other papers by Joanna IntHout in
Google Scholar
PubMed
Search for other papers by Hedi L Claahsen-van der Grinten in
Google Scholar
PubMed
Search for other papers by the dsd-LIFE Group in
Google Scholar
PubMed
engagement, age of diagnosis, testosterone therapy and physical and mental health status, and to compare values to a European Social Surveys (ESS) reference population. Methods Study population This study was part of the European dsd-LIFE study, a
Search for other papers by Mikkel Andreassen in
Google Scholar
PubMed
Search for other papers by Anders Juul in
Google Scholar
PubMed
Search for other papers by Ulla Feldt-Rasmussen in
Google Scholar
PubMed
Search for other papers by Niels Jørgensen in
Google Scholar
PubMed
with pituitary diseases were offered cryopreservation of semen for future fertility treatment before testosterone therapy was initiated, or in selected younger cases before pituitary surgery or radiation therapy. All patients who started testosterone
Department of Endocrinology, St James’s Hospital, Dublin, Ireland
Search for other papers by Agnieszka Pazderska in
Google Scholar
PubMed
Search for other papers by Yaasir Mamoojee in
Google Scholar
PubMed
Search for other papers by Satish Artham in
Google Scholar
PubMed
Search for other papers by Margaret Miller in
Google Scholar
PubMed
Department of Endocrinology, University of Manchester, Manchester, UK
Search for other papers by Stephen G Ball in
Google Scholar
PubMed
Department of Paediatric Endocrinology & Diabetes, Newcastle-upon-Tyne Hospitals, Newcastle upon Tyne, UK
Search for other papers by Tim Cheetham in
Google Scholar
PubMed
Endocrine Research Group, Institute of Genetic Medicine, University of Newcastle-upon-Tyne, Newcastle upon Tyne, UK
Search for other papers by Richard Quinton in
Google Scholar
PubMed
remainder being identifiable later during the process of pubertal induction through failure to normalise testicular volume with testosterone therapy ( 1 ). Given the aforementioned factors, the diagnostic evaluation and management of pubertal delay should
Search for other papers by Sebastian Franik in
Google Scholar
PubMed
Search for other papers by Kathrin Fleischer in
Google Scholar
PubMed
Search for other papers by Barbara Kortmann in
Google Scholar
PubMed
Search for other papers by Nike M Stikkelbroeck in
Google Scholar
PubMed
Search for other papers by Kathleen D’Hauwers in
Google Scholar
PubMed
Search for other papers by Claire Bouvattier in
Google Scholar
PubMed
Search for other papers by Jolanta Slowikowska-Hilczer in
Google Scholar
PubMed
Search for other papers by Solange Grunenwald in
Google Scholar
PubMed
Search for other papers by Tim van de Grift in
Google Scholar
PubMed
Search for other papers by Audrey Cartault in
Google Scholar
PubMed
Search for other papers by Annette Richter-Unruh in
Google Scholar
PubMed
Search for other papers by Nicole Reisch in
Google Scholar
PubMed
Search for other papers by Ute Thyen in
Google Scholar
PubMed
Search for other papers by Joanna IntHout in
Google Scholar
PubMed
Search for other papers by Hedi L Claahsen-van der Grinten in
Google Scholar
PubMed
Search for other papers by the dsd-LIFE group in
Google Scholar
PubMed
‘Are you on testosterone therapy at present? SC Yes No Age at diagnosis ‘At what age was your condition diagnosed?’ SC Before birth At birth (0–1 month) Infancy (1 month–3 years) Childhood (4
Search for other papers by Jennifer K Y Ko in
Google Scholar
PubMed
Search for other papers by Thomas F J King in
Google Scholar
PubMed
Search for other papers by Louise Williams in
Google Scholar
PubMed
Search for other papers by Sarah M Creighton in
Google Scholar
PubMed
Search for other papers by Gerard S Conway in
Google Scholar
PubMed
are gradually being phased out because of the increased risk of thrombosis ( 4 ). Oestradiol implants are not widely available in the United Kingdom. Commonly available option for testosterone therapy in the United Kingdom includes 2% transdermal gel